Skip to content
MARKETS / NASDAQ / PSNL
NASDAQ · SERVICES-MEDICAL LABORATORIES · SMALL CAP

Personalis, Inc. PSNL

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$69.6M
▼ 17.7% YoY
$-81.3M
$-79.5M
In brief

What this company does

Personalis develops, markets, and sells advanced cancer genomic testing services. We were incorporated under the laws of the state of Delaware in 2011 under the name Personalis, Inc. and became a publicly-traded company in 2019. Our customers include global pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. As of January 31, 2026, we had 260 employees, of which 259 were full-time employees.

Written from the business description in Personalis, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth
USD 69.6M
Revenue, FY2025 · full 9-year series below
Revenue $M Net income $M
FY2025 · Revenue 69.6 · Net income -81.3
40M80M-40M-80M201720182019202020212022202320242025
Compound annual growth
+2.3%
−2.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −2.4% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−117 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -126.4% · Net -116.7%
-100%-200%201720182019202020212022202320242025
ROE
FY2025 · ROE -35.0%
-5000%-10000%-15000%201720182019202020212022202320242025

Each USD of equity lost 35 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -79.5
-50M-100M201720182019202020212022202320242025

Total assetsUSD 334.2M
EquityUSD 261.2M
CashUSD 124.2M
Current ratio6.76×

Equity funds 78% of total assets.

The 9-year record
9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017
Revenue $B0.10.10.10.10.10.10.10.00.0
Operating income $B−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0
EBITDA $B−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.00.00.00.0
Net income $B−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0
Free cash flow $B−0.1−0.0−0.1−0.1−0.1−0.0−0.0−0.0−0.0
EPS, diluted $−0.91−1.37−2.25−2.48−1.49−1.20−1.39−6.49−7.78
Dividend / sh $·········
Payout %·········
ROE %−35.0−48.9−62.3−42.9−25.8−27.4−16611.9··
Shares out B0.100.090.050.050.040.040.030.00·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 34 reconciliationsAUDITED

Reconciled in 9 of 19 fiscal years. 52 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityServices-Medical Laboratories
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2017

Share this section

Download image